These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 35436607)
1. The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time. Negro F; Caravelli P; Morganti R; Casini M; Ruocco L; Tripodi A; De Caterina R Vascul Pharmacol; 2022 Jun; 144():106994. PubMed ID: 35436607 [TBL] [Abstract][Full Text] [Related]
2. Differences in activated clotting time and total unfractionated heparin dose during pulmonary vein isolation in patients on different anticoagulation therapy. Zeljkovic I; Brusich S; Scherr D; Velagic V; Traykov V; Pernat A; Anic A; Szavits Nossan J; Jan M; Bakotic Z; Pezo Nikolic B; Radeljic V; Bojko A; Benko I; Manola S; Pavlovic N Clin Cardiol; 2021 Aug; 44(8):1177-1182. PubMed ID: 34196416 [TBL] [Abstract][Full Text] [Related]
3. Activated Clotting Time Monitoring during Atrial Fibrillation Catheter Ablation: Does the Anticoagulant Matter? Martin AC; Kyheng M; Foissaud V; Duhamel A; Marijon E; Susen S; Godier A J Clin Med; 2020 Jan; 9(2):. PubMed ID: 32012701 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243 [No Abstract] [Full Text] [Related]
5. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924 [TBL] [Abstract][Full Text] [Related]
6. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303 [TBL] [Abstract][Full Text] [Related]
8. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke. Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229 [TBL] [Abstract][Full Text] [Related]
9. Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment. Zhang RF; Ma CM; Wang N; Yang MH; Li WW; Yin XM; Dong YX; Yu XH; Xiao XJ; Xia YL; Gao LJ BMC Cardiovasc Disord; 2021 Apr; 21(1):214. PubMed ID: 33906609 [TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Skjøth F; Larsen TB; Rasmussen LH; Lip GY Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485 [TBL] [Abstract][Full Text] [Related]
12. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. Lee SI; Sayers M; Lip GY; Lane DA Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557 [TBL] [Abstract][Full Text] [Related]
13. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation. Brown JD; Shewale AR; Talbert JC J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556 [TBL] [Abstract][Full Text] [Related]
14. Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants. Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Komtasubara I; Kusachi S Clin Drug Investig; 2016 Oct; 36(10):837-48. PubMed ID: 27389243 [TBL] [Abstract][Full Text] [Related]
15. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study. Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386 [TBL] [Abstract][Full Text] [Related]
18. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Staerk L; Fosbøl EL; Lip GYH; Lamberts M; Bonde AN; Torp-Pedersen C; Ozenne B; Gerds TA; Gislason GH; Olesen JB Eur Heart J; 2017 Mar; 38(12):907-915. PubMed ID: 27742807 [TBL] [Abstract][Full Text] [Related]